Cardiovascular and all‐cause mortality in prostatic cancer patients treated with estrogens or orchiectomy as compared to the standard population

@article{Aro1991CardiovascularAA,
  title={Cardiovascular and all‐cause mortality in prostatic cancer patients treated with estrogens or orchiectomy as compared to the standard population},
  author={J. Aro},
  journal={The Prostate},
  year={1991},
  volume={18}
}
  • J. Aro
  • Published 1991
  • Medicine
  • The Prostate
Four hundred and seventy‐seven prospectively randomized patients with prostatic carcinoma were treated with a combination of intramuscular polyestradiol phosphate (PEP) and oral ethinyl estradiol, with intramuscular PEP alone, or with orchiectomy. The cardiovascular and all‐cause mortality of the two estrogen therapy modalities and orchiectomy were compared with those of the Finnish male population in general. The age‐standardized rate ratios (∼ relative risk) for cardiovascular mortality and… Expand
Parenteral polyoestradiol phosphate vs orchidectomy in the treatment of advanced prostatic cancer. Efficacy and cardiovascular complications: a 2-year follow-up report of a national, prospective prostatic cancer study. Finnprostate Group.
TLDR
Parenteral PEP (240 mg/month) seems to be as efficient as orchidectomy in inhibiting disease in patients with advanced prostatic cancer, and the difference was statistically significant during the first year of treatment. Expand
Gastrectomy for Early Gastric Cancer is Associated with Decreased Cardiovascular Mortality in Association with Postsurgical Metabolic Changes
TLDR
Patients with EGC who undergo gastrectomy have a lower cardiovascular mortality but similar all-cause mortality as that of the general population, and a significant reduction in body weight and visceral fat after surgery may improve impaired lipid metabolism and prevent atherosclerotic changes. Expand
Parenteral estrogen versus total androgen ablation in the treatment of advanced prostate carcinoma: effects on overall survival and cardiovascular mortality. The Scandinavian Prostatic Cancer Group (SPCG)-5 Trial Study.
TLDR
The current parenteral estrogen regimen seems to be of comparable efficacy and cardiovascular safety as TAA in terms of overall survival and PEP has by far the lowest drug cost and also the lowest cumulative direct costs and thus has the highest cost-effectiveness. Expand
Transdermal estradiol therapy for advanced prostate cancer--forward to the past?
TLDR
Transdermal estradiol therapy prevented andropause symptoms, improved quality of life scores and increased bone density, with the potential for considerable economic savings over conventional hormone therapies. Expand
Advanced Prostate Cancer
TLDR
The aim of intermittent androgen suppression is to increase quality of life during treatment-free periods and to maintain the androgen dependency of the malignant cells. Expand
Therapy Insight: parenteral estrogen treatment for prostate cancer—a new dawn for an old therapy
TLDR
Parenteral estrogen therapy has the advantage of giving protection against the effects of andropause, which are induced by conventional androgen suppression and include osteoporotic fracture, hot flashes, asthenia and cognitive dysfunction. Expand
Comparison of a long-acting LHRH agonist and polyoestradiol phosphate in the treatment of advanced prostatic carcinoma. An open prospective, randomized multicentre study.
TLDR
In locally advanced (M0) and histologically well or moderately differentiated tumours, LHRH agonist therapy was considerably more effective than oestrogen as regards time to progression of the carcinoma, but in metastatic (M1) and Histologically poorly differentiated tumour both methods gave similar results. Expand
Review Article ESTROGENS IN THE TREATMENT OF PROSTATE CANCER
TLDR
Comparing the efficacy, complications and cost of regimens containing oral estrogens or parented estrogens with agents that increase efficacy and decrease toxicity to results of other regimens, such as combined androgen blockade, should be done to determine if an estrogencontaining regimen could lower the cost of treating advanced prostate cancer. Expand
androgen deprivation therapy for prostate cancer - the potential of parenteral estrogen
TLDR
Parenteral estrogen therapy is protection against the effects of the andropause (cf female menopause), which with conventional androgen suppression causes significant morbidity including osteoporotic fracture, hot flushes, lethargy and cognitive dysfunction. Expand
Estrogens in the treatment of prostate cancer.
TLDR
Comparisons of regimens containing oral estrogens or parenteral estrogens with agents that increase efficacy and decrease toxicity to results of other regimens, such as combined androgen blockade, should be done to determine if an estrogen-containing regimen could lower the cost of treating advanced prostate cancer. Expand
...
1
2
3
...

References

SHOWING 1-10 OF 23 REFERENCES
Cardiovascular complications to treatment of prostate cancer with estramustine phosphate (Estracyt) or conventional estrogen. A follow-up of 212 randomized patients.
TLDR
Cardiovascular complications categorized as impaired arterial circulation including ischemic heart disease, venous thromboembolism, cardiac incompensation and cerebral depression were found to be equally frequent following the two different forms of treatment. Expand
Orchidectomy versus oestrogen for prostatic cancer: cardiovascular effects.
TLDR
The substantially increased risk of cardiovascular complications in patients given oestrogen for prostatic cancer warrants careful consideration when choosing treatment for this disorder. Expand
Cardiovascular complications in the treatment of prostatic carcinoma.
TLDR
It is recommended that stilboestrol and estramustine phosphate should not be used in the presence of cardiovascular disease and that the primary form of treatment in prostatic carcinoma should be bilateral orchiectomy, especially in patients with localised disease. Expand
Incidence of cardiovascular disease and death in patients receiving diethylstilbestrol for carcinoma of the prostate
Patients treated with a 5.0‐mg daily dose of diethylstilbestrol (DES) had an increased incidence of fatal and non‐fatal cardiovascular disease when compared to placebo in all stages of prostaticExpand
Treatment of prostatic carcinoma with polyestradiol phosphate combined with ethinylestradiol.
  • G. Jönsson
  • Medicine
  • Scandinavian journal of urology and nephrology
  • 1971
TLDR
Combined treatment with Estradurin and a stronger inhibitor of gonadotropin might be more effective in patients with prostatic carcinoma, which has a firm diagnosis of carcinoma. Expand
Comparison of endocrine and radiation therapy in locally advanced prostatic cancer.
TLDR
During the 4-year follow-up period there were no significant differences in the progression rates and the frequency of thromboembolic and other cardiovascular complications was highest in the estrogen group, while in the radiotherapy group, 19 of 45 patients had bowel or bladder complications. Expand
Cardiovascular follow‐up of patients with prostatic cancer treated with single‐drug polyestradiol phosphate
TLDR
Patients with cancer of the prostate treated with strict parenteral estrogen in the form of monthly polyestradiol phosphate injections have responded to therapy and there have been no cardiovascular complications at a mean follow‐up of 12.9 ± 0.7 months. Expand
Hormonal Therapy of Prostatic Cancer
TLDR
Three VACURG studies report that patients with low stage disease who are treated with estrogen have a higher death rate than men not receiving estrogen and in patients with high stage disease, delayed hormonal therapy is as effective as early hormonal therapy. Expand
Effects of orchiectomy and polyestradiol phosphate therapy on serum lipoprotein lipids and glucose tolerance in prostatic cancer patients.
TLDR
PEP treatment caused changes in the serum lipoprotein pattern, which apparently decreases the risk of atherosclerosis. Expand
High dose polyoestradiol phosphate with and without acetosalicylic acid versus orchiectomy in the treatment of prostatic cancer. Finnprostate Group.
TLDR
It was concluded that parenteral high dose PEP is not associated with an increased risk of cardiovascular complications and there is no need for daily low dose ASA. Expand
...
1
2
3
...